Zydus Pharmaceuticals (USA) Inc recalls

7 recalls.

• Hydrocortisone Sodium Succinate for Injection recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported October 21, 2026 · Failed Impurities/Degradation Specifications.
• Mirabegron Extended-Release Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported August 12, 2026 · CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
• Erythromycin Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported May 27, 2026 · CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
• Erythromycin Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported May 27, 2026 · CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
• Icosapent Ethyl Capsules recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported March 18, 2026 · Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
• Icosapent Ethyl capsules recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIReported January 28, 2026 · Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules
• traZODONE Hydrochloride Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIIReported January 7, 2026 · Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.